Rhythm will use Camurus' drug delivery technology, FluidCrystal ®, to formulate its once-weekly obesity drug candidate, setmelanotide (RM-493), then develop, manufacture, and commercialize the new ...
Daylight savings ends on November 2. Here's how the time change affects your health, and how you can readjust your internal clock.
Rhythm Pharmaceuticals, Inc.'s main asset, imcivree, targets rare genetic obesity disorders; key milestones in 2025 could significantly impact the stock. Positive Phase 3 data and expanded indications ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback